Aspen Pharmacare (OTCMKTS:APNHY) & Personalis (NASDAQ:PSNL) Head-To-Head Contrast

Personalis (NASDAQ:PSNL) and Aspen Pharmacare (OTCMKTS:APNHY) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, earnings and profitability.

Analyst Ratings

This is a summary of recent ratings for Personalis and Aspen Pharmacare, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	0	0	5	0	3.00
Aspen Pharmacare	0	0	0	0	0.00

Personalis currently has a consensus target price of $7.42, suggesting a potential upside of 25.07%. Given Personalis’ stronger consensus rating and higher possible upside, analysts plainly believe Personalis is more favorable than Aspen Pharmacare.

Profitability

This table compares Personalis and Aspen Pharmacare’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Personalis	-113.70%	-47.57%	-35.05%
Aspen Pharmacare	N/A	N/A	N/A

Risk and Volatility

Personalis has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Aspen Pharmacare has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.

Insider and Institutional Ownership

61.9% of Personalis shares are owned by institutional investors. 3.8% of Personalis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Personalis and Aspen Pharmacare”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$80.32 million	6.55	-$81.28 million	($1.28)	-4.63
Aspen Pharmacare	$2.39 billion	N/A	-$59.64 million	N/A	N/A

Aspen Pharmacare has higher revenue and earnings than Personalis.

Summary

Personalis beats Aspen Pharmacare on 6 of the 11 factors compared between the two stocks.

About Personalis

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

About Aspen Pharmacare

Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.